tension system. Others give evidence that potassium might modify peripheral and central neural regulation of blood pressure. We can draw no conclusions from our study about the way that potassium acts. Nor is there a ready explanation for a possible mechanism of sodium-potassium interaction. Finally, there remains a possibility that potassium intake and the urinary sodium to potassium ratio are indicators of another, as yet unknown, determinant of blood pressure change in childhood rather than being direct causal factors in blood pressure regulation.

In conclusion, this study supports the view that dietary potassium and the dietary sodium to potassium ratio may be important in the early pathogenesis of hypertension. Possibly a sufficient intake of potassium or a reduction of the dietary sodium to potassium ratio in youth may prove to be beneficial in the early prevention of hypertension.


(Accepted 3 February 1990)

Long term propranolol treatment and changes in body weight after myocardial infarction

Stephan Rössner, Carol L Taylor, Robert P Byington, Curt D Furberg

Department of Public Health Sciences, Bowman-Gray School of Medicine, Winston-Salem, North Carolina 27103, United States
Stephan Rössner, MD, visiting professor
Carol L Taylor, MAS, statistician
Robert P Byington, PhD, assistant professor
Curt D Furberg, PhD, chairman

Correspondence to: Dr S Rössner, Obesity Unit, Karolinska Hospital, S-104 01 Stockholm, Sweden.


Abstract

Objective—To determine the effect of long term propranolol treatment on body weight.

Design—Retrospective analysis of data from a placebo controlled randomised double blind clinical trial (the β blocker heart attack trial).

Patients—3837 Men and women randomised 5-21 days after an acute myocardial infarction to treatment with placebo or propranolol for up to 40 months. Patients were followed up at annual visits.

Main outcome measure—Changes in body weight.

Results—At the first annual visit patients treated with propranolol had gained more weight than those given placebo (mean weight gain 2·3 kg v 1·2 kg respectively, mean difference 1·2 kg (95% confidence interval 0-9 to 1·5)). These group differences remained at the second and third annual visits. The difference in weight gain could not be explained by discrepancies in the use of diuretics or in physical activity and was similar in patients of both sexes and of all ages.

Conclusion—Long term β blockade results in a sustained weight gain.

Introduction

Recently it has become increasingly clear that obesity is a multifactorial condition. Though the development of obesity implies at least a temporary positive energy balance, factors that explain why some people become overweight and others do not have been surprisingly difficult to identify. A recent study showing that large eaters in fact weighed less than small eaters has underscored the complexity of the problem. As the autonomic system affects energy metabolism 1 alterations in autonomic activity might be expected to promote obesity in some human subgroups. Despite numerous studies showing the effects of β-blockade on thermogenesis it has been argued that long term β blockade does not result in weight gain in humans. This might be because small drug induced increases in weight over time are obscured by the continuous increase in body weight seen with age. We used data from the β-blocker heart attack trial to analyse retrospectively the effect of long term treatment with propranolol compared on placebo in weight gain in patients who had had a myocardial infarction.

Patients and methods

A detailed description of the design of the β-blocker heart attack trial and its methods has been reported elsewhere. In summary, 3837 men and women who had survived an acute myocardial infarction were randomised within five to 21 days after the infarction to treatment with propranolol or placebo. During an average follow up of 25 months mortality from all causes and fatal and non-fatal myocardial infarctions were significantly reduced. We analysed height, body weight, and heart rate at baseline and after one, two, and three years of follow up from the trial database by sex, age, concomitant use of diuretics, and reported changes in physical activity. We used a multivariate repeated measures analysis of covariance that adjusted for age, sex, and use of diuretics to determine the possible effect of propranolol on body weight. As a large proportion of subjects were not followed up for two or three years several estimation methods were applied, which produced the
same results as analyses based on the patients with complete follow up data.\text实地

**Results**

At the start of the trial the mean age of the 3837 patients (602 women) was 55.3 years and the median body mass index 25.0 kg/m\(^2\). The fifth and 95th centiles being 19.9 kg/m\(^2\) and 33.3 kg/m\(^2\). The mean weight changes in all patients are summarised in the figure. In both groups there was an increase in weight after one year, when 1648 patients remained in the placebo group and 1679 in the propranolol group. In the placebo group the mean weight increased from 77.9 kg to 79.1 kg and in the propranolol group from 78.2 kg to 80.5 kg, a mean difference of 1.2 kg with a 95% confidence interval of 0.9 to 1.5. The corresponding figures at one year for both sexes were similar.

![Graph showing weight changes over three years](image)

**Discussion**

The mean body weight in many countries in the Western world increases steadily with age and therefore tends to fall again in the seventh decade of life. Minor changes in weight from other causes may therefore be overlooked unless placebo controlled data are available. Our results show that during long term treatment with propranolol weight increased significantly and in addition to the increase attributable to aging. This increase remained when age, sex, and baseline weight were adjusted for. Our patients had survived a myocardial infarction, and we do not know to what extent our results can be extrapolated to other groups of patients taking β blockers or adrenergic agents long term.

The fact that consistent findings were obtained in several subgroups indicates that the differences in weight reflect a true effect of propranolol. The mechanism of action remains unclear. In this study we were not able to determine which body tissues increased in weight. Fluid retention is not, however, an established side effect of treatment with β blockers.

It could be argued that patients treated with placebo might require more diuretics for their ensuing cardiovascular problems. In the placebo group the proportion of diuretic users was slightly higher at the one year follow up visit, but this pattern was inconsistent (+3.0% after one year, −0.3% after two years, and +2.7% after three years) and seems too small to account for the systematic weight differences.

Patients taking β blockers might be more capable of performing physical activity than patients taking placebo, but such increased energy expenditure would most likely have led to a lower weight in the patients taking propranolol, which suggests that the difference in weight was underestimated. Questionnaire data on reported physical activity, however, showed no difference between the groups at any time.

The mean increase in body weight that could be attributed to propranolol was moderate. In some patients, however, even such a moderate weight increase could be clinically important.

SR was awarded a visiting scholarship at Bowman-Gray School of Medicine to carry out this study.

---


(Accepted 11 January 1990)